No Data
Express News | IGC Pharma Annonuces Mouse Studies Showing Reduction In Amyloid Plaque With TGR-63: 78% In Cortex And 85% In Hippocampus
Express News | IGC Pharma Inc: Expects to Begin a Phase 1 Trial for Tgr-63 in 2025
Express News | IGC Pharma Inc: Mouse Studies Demonstrate Significant Reduction in Amyloid Plaque: 78% In Cortex and 85% in Hippocampus
Express News | IGC Pharma's Tgr-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
IGC Pharma Q4 2024 GAAP EPS $(0.04), Sales $295.000K Beat $193.000K Estimate
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.04) per share. The company reported quarterly sales of $295.000 thousand which beat the analyst consensus estimate of $193.000 thousand by 52.85
India Globalization Capital GAAP EPS of -$0.22 In-line, Revenue of $1.35M Beats by $0.11M